Bartlett, J M S <br/><br/>
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial.  [electronic resource] 

 -  British journal of cancer  Oct 2013 
 - 2453-61 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2013.609  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Androstadienes--therapeutic use<br/>Aromatase Inhibitors--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>ErbB Receptors--metabolism<br/>Female<br/>Humans<br/>Middle Aged<br/>Molecular Sequence Data<br/>Prognosis<br/>Prospective Studies<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Selective Estrogen Receptor Modulators--therapeutic use<br/>Tamoxifen--therapeutic use<br/>Tissue Array Analysis